Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Valentin, T; Leitner, E; Rohn, A; Zollner-Schwetz, I; Hoenigl, M; Salzer, HJ; Krause, R.
Rifaximin intake leads to emergence of rifampin-resistant staphylococci.
J Infect. 2011; 62(1): 34-38.
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Hönigl Martin
Krause Robert
Leitner-Meyer Eva
Salzer Helmut J. F.
Valentin Angelika
Valentin Thomas
Zollner-Schwetz Ines
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
Objectives: Rifaximin is a poorly absorbed non-systemic antimicrobial agent used in various gastrointestinal disorders. Rifampin is pivotal for the treatment of staphylococcal foreign body infections and resistance develops rapidly during monotherapy. The close structural relation of rifaximin to rifampin may lead to cross-resistance. The aim of our study was to determine whether rifampin-resistance emerges in human skin staphylococci during or after oral intake of rifaximin. Methods: Rifampin resistance of skin staphylococci in healthy volunteers during and after intake of rifaximin was determined by E-Test. Results: Seven out of eleven volunteers developed rifampin-resistant staphylococci after intake of rifaximin. A total of eleven rifampin-resistant and three rifampin-intermediate staphylococcal isolates were found. Before or during intake no resistant isolate was detected. Shortly after discontinuation the rifampin-resistant strains were primarily isolated from the perianal skin, a few weeks later they were found more frequently on the skin of the hands and lower arms. Conclusion: Our data show that rifampin-resistant staphylococci emerge after intake of rifaximin. Since rifampin resistance is associated with treatment failure in staphylococcal foreign body infections, we conclude that rifaximin should be avoided in patients at risk for these infections. (C) 2010 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Administration, Oral -
Adult -
Anti-Bacterial Agents - pharmacology
Anti-Infective Agents - administration and dosage
Drug Resistance, Bacterial - drug effects
Female -
Gastrointestinal Agents - administration and dosage
Humans -
Male -
Middle Aged -
Rifampin - pharmacology
Rifamycins - administration and dosage
Skin - microbiology
Staphylococcal Infections - drug therapy
Staphylococcus - drug effects

Find related publications in this database (Keywords)
Rifampin
Rifaximin
Resistance
Foreign body infections
© Meduni Graz Impressum